Clinical trials: Protein Digestion
Advanced Solid Tumors, Hepatocellular Carcinoma
A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy
This is a two-part trial. "Solid tumor" in this protocol means solid tumor excluding hepatocellular carcinoma (HCC). Part 1: Dose Escalation Phase in subjects with solid tumor (Cohort A) and HCC (Cohort B).
- Trial name
- NCT01668017
- Testing
- Pimasertib
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Milk Hypersensitivity, Food Sensitivity
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
The aim of the study is to show the efficacy, tolerance and nutritional adequacy of a newly developed hydrolyzed rice formula in infants with a proven cow's milk protein allergy.
- Conditions
- Milk Hypersensitivity, Food Sensitivity, Protein Allergy
- Trial name
- Paradice (NCT01998074)
- Testing
- extensively hydrolyzed rice protein formula
- Where
- Belgium
- Sponsor
- United Pharmaceuticals
Gastrointestinal Stromal Tumor (GIST)
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
This is a Phase II, non-randomized, open-label, multi-center study conducted in the USA. The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence…
- Trial name
- NCT00867113
- Testing
- imatinib mesylate
- Where
- 21 sites in United States
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Pancreatic Cancer
Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer
LE-DT is a novel, proprietary delivery system of docetaxel developed by NeoPharm, Inc. Docetaxel (currently marketed as Taxotere) is an anti-microtubule agent that prevents cell division.
- Trial name
- NCT01186731
- Testing
- Liposome Entrapped Docetaxel (LE-DT)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- INSYS Therapeutics Inc
Liver Cancer
GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Liver Cancer
This trial is to further study the safety and effectiveness of autologous gp96 treatment of liver cancer on the basis of preliminary work
- Trial name
- NCT04206254
- Testing
- gp96
- Volunteers
- 80 people
- Sponsor
- Cure&Sure Biotech Co., LTD
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
HIV Infections, Hepatitis C
Treatment of Hepatitis C in Hemophilic Patients With HIV
Pegylated interferon (PEG-interferon) and ribavirin are accepted treatments for hepatitis C virus (HCV) infection. However, HCV infection progresses differently in patients who are coinfected with HIV and in hemophiliacs.
- Conditions
- HIV Infections, Hepatitis C, Hemophilia
- Trial name
- NCT00055341
- Testing
- Peginterferon alfa-2a, Ribavirin
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Obesity, Abdominal, Hyperlipidemias
Obesity-related Health Benefits of Apples
Obesity is characterized by an underlying inflammatory state in which various inflammatory signaling molecules, termed cytokines, affect metabolic processes central to type 2 diabetes and cardiovascular disease; leading causes of…
- Conditions
- Obesity, Abdominal, Hyperlipidemias, Inflammation, Dysbiosis
- Trial name
- NCT03523403
- Testing
- Apples
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- University of Guelph
Anemia, Multiple Myeloma
The Effect of Epoetin Alfa on the Anemia of Patients With Selected Cancers Receiving Chemotherapy
The purpose of this study is to evaluate the safety and effectiveness of epoetin alfa versus placebo in reducing or preventing the need for transfusions in anemic patients with cancer receiving chemotherapy, and to investigate…
- Conditions
- Anemia, Multiple Myeloma, Lymphoma, Breast Cancer
- Trial name
- NCT00270166
- Testing
- epoetin alfa
- Volunteers
- 201 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
End-stage Liver Disease, Liver Cirrhosis
Nutrition and Exercise Prehabilitation in Patients Awaiting Liver Transplantation
This study aims to evaluate the effects of a diet with even protein distribution plus exercise (Group A) versus a diet with skewed protein distribution plus exercise (Group B) versus standard dietary and physical activity advice…
- Conditions
- End-stage Liver Disease, Liver Cirrhosis, Liver Transplantation, Malnutrition
- Trial name
- POWER-LT (NCT07561138)
- Testing
- Diet with even protein distribution plus exercise program, Diet with skewed protein distribution plus exercise program, Standard dietary and physical activity advice
- Where
- 2 sites in Greece
- Volunteers
- 90 people
- Sponsor
- Kalliopi Anna Poulia
Metastatic Pancreatic Cancer, Pancreatic Cancer
High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer
The purpose of this study is to see if a combination of paclitaxel protein bound (also known as nab-paclitaxel), gemcitabine, and cisplatin when given with high dose Ascorbic Acid will be safe and effective in individuals with…
- Conditions
- Metastatic Pancreatic Cancer, Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable
- Trial name
- NCT03908333
- Testing
- Ascorbic Acid, Paclitaxel protein-bound, Cisplatin
- Where
- 6 sites in United States
- Sponsor
- Medical College of Wisconsin
General Surgery, Cancer of Colon
Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
Immunomodulating nutrition is supposed to reduce the number of complications and the legnth of the hospital stay during the postoperative period in patients after major gastrointestinal surgery.
- Trial name
- Preop immuno (NCT03980704)
- Testing
- IMPACT, resource protein
- Where
- Poland
- Volunteers
- 299 people
- Sponsor
- Stanley Dudrick's Memorial Hospital
Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease
Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Cell-free fetal DNA (cffDNA) is present in the maternal blood from the early first trimester of gestation and makes up 5%-20% of the total circulating cell-free DNA (cfDNA) in maternal plasma.
- Conditions
- Invasive PreNatal Diagnosis in a Context of Family History of Single-gene Disorders, Including, Sickle Cell Disease, Cystic Fibrosis, Fragile X Syndrome
- Trial name
- DANNIgene (NCT06147414)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 550 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Cystic Fibrosis
Cystic Fibrosis Foundation (CFF) Biomarkers of Exacerbation
Clinical and translational research in cystic fibrosis (CF) is hampered by a lack of biomarkers that can be used to identify promising new therapies.
- Trial name
- NCT00788359
- Where
- 5 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Colorado, Denver
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Crohn's Disease
Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA )
This is a multi-center study that explores the relationship between recapture of response with escalation to weekly adalimumab and trough adalimumab concentration before escalation in patients experiencing lack of response (LOR).
- Trial name
- PRADA (NCT02896985)
- Where
- 24 sites in Canada
- Volunteers
- 98 people
- Sponsor
- AbbVie
Breast Carcinoma, Colon Carcinoma
Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
This research trial studies how well biospecimen collection works in identifying genetic changes in patients with breast, prostate, colorectal, liver, or kidney cancer or multiple myeloma undergoing surgery.
- Conditions
- Breast Carcinoma, Colon Carcinoma, Invasive Carcinoma, Kidney Carcinoma
- Trial name
- NCT04955808
- Testing
- Biospecimen Collection, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 2,400 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer
Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to and kill tumor cells. Combining vaccine therapy with surgery may be an effective treatment for pancreatic cancer.
- Trial name
- NCT00003025
- Testing
- vitespen
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis
Transcriptome and Metabolic Analyses of CHAPLE Disease
CHAPLE syndrome (complement hyperactivation, angiopathic thrombosis, protein losing enteropathy) is a newly discovered genetic disorder, which is caused by deleterious mutations in the CD55 gene.
- Conditions
- CD55 - Cluster of Differentiation Antigen 55 Deficiency, Primary Intestinal Lymphangiectasis, Protein-Losing Enteropathies, Complement Regulatory Factor Defect
- Trial name
- CHAPLEOMIC (NCT03950804)
- Testing
- Eculizumab Injection
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Marmara University